Is Charles River Laboratories (CRL) a risky stock?
As of July 21, 2026, Clavix grades Charles River Laboratories (CRL) B- for risk, a composite score of 63 out of 100 on an A+ to F scale, which puts CRL in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind CRL's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how CRL scores on each, as of July 21, 2026.
What's moving CRL's risk right now
Company-specific signals Clavix flags behind CRL's current grade, drawn from recent news and filings as of July 21, 2026.
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call
The collaboration reinforces CRL's positioning in the high-growth cell and gene therapy services market, adding incremental NGS revenue while demonstrating continued demand for it…
Valuation is in line with peers and growth expectations, leaving the stock a hold until a re-rating catalyst emerges.
What a B- grade means
On the Clavix A+ to F scale, CRL's composite of 63 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell CRL or any security. Grades are risk indicators, not predictions of return. Data may be delayed.